Forums

@Zylmaster, mesmo com as poucas coisas que escreves neste tópico, eu sou capaz de arriscar que tu és da área da enfermagem, fisioterapia ou afins, e que terás uma idade < 35 anos, será que eu estou próximo da realidade?

Que vantagem têm no fronted?

Testei com e sem Fronted ligado e foi recusado em ambos os casos, testei Wizink direto e deu. O Curve deve andar a cortar neste tipo de utilizações.

Fui o único a deixar de receber notificações deste tópico?

O fundo CS (Lux) Digital Health Equity B USD (ISIN: LU1683285164) do setor da biotecnologia existe na morningstar.pt, que juntamente com outro FI (não retalho) do Credit Suiss são os FI com maiores retornos a 1 ano e YTD do setor da biotecnologia. Acontece, que no site Citywire aquele fundo não foi incluído na biotecnologia nem na saúde, mas sim em "Global Themes", estando a 1 ano classificado em 1.º lugar no Total Return e na Max Drawdown num total de 51 fundos: https://citywire.co.uk/funds-insider/sector/equity-global-themes-funds/i597/?periodMonths=12&page=1&sortBy=maxdrawdown Como o banco Best não trabalhava com a gestora de ativos do Credit Suiss, solicitei ao Best no sentido de verem se podiam vir a incluir este FI e outros do CS, tendo-me já telefonado a informar que já têm o processo em andamento na CMVM e que já podia fazer a subscrição "em papel" pois a CMVM pode demorar 4 semanas a analisar o assunto e só depois é que o FI fica disponibilizado na plataforma do Best.  O fundo CS (Lux) Digital Health Equity B USD juntamente com o FI Janus Henderson Horizon Biotechnology A2 USD Acc já existente no Best, que no site da Citywire está classificado a 1 ano em 1.º lugar no Total Return e na Max Drawdown da biotecnologia no total de 8 FI (https://citywire.co.uk/sector/equity-biotechnology-funds/i2162?periodMonths=12&page=1), fazem com que o Best fique com umas das melhores ofertas de FI a nível mundial na área da biotecnologia/Saúde. Em relação ao "Digital Health" do FI do CS, vejam o que foi escrito há cerca de 1 ano sobre esta temática de "Digital Therapeutics", no seguinte artigo: Digital Therapeutics Explained: DTx market trends & top companies delivering on the latest digital health opportunity. A new class of medicine — digital therapeutics (DTx) — has emerged, offering a novel means of treating the swelling number of patients with chronic diseases and keeping associated costs down. What is Digital Therapeutics (DTx)? Digital therapeutics deliver evidence-based therapies via software — often in the form of consumer-facing mobile health apps — that replace or complement the existing treatment of a disease. They diverge from the broader digital health market in that they must be approved by regulatory bodies — and displaying proof-of-concept is at the core of their model.  DTx vendors leverage their tech to treat chronic conditions, which gobble up the lion's share of the US' healthcare spending: Business Insider Intelligence estimates that the US shelled out up to $3.3 trillion on chronic disease in 2018. The surging prevalence of chronic conditions combined with their sky-high price tags is fueling fast growth in the global DTx market, which is poised to expand 21% annually to hit nearly $9 billion by 2025.  The sea change sparked by the advent of digital medicines threatens to reshape the entire healthcare value chain. Because drugs interact with nearly every healthcare stakeholder, DTx solutions are leading a variety of players to carve out room for digital solutions: Pharmacy benefit managers (PBMs) are creating logs for DTx as they would drugs, insurers are linking their members up with digital solutions in an effort to mitigate spending, and entrenched pharma and medtech companies are tying up with DTx vendors to dip into new revenue streams. Those that choose not to get on the DTx bandwagon might miss out on a massive opportunity — and we think laggard drugmakers and medical device makers that don't jump at the chance of linking up with DTx providers could put themselves at risk of losing market share to new competitors.  In this report, Business Insider Intelligence will explore the drivers lighting a fire under the DTx market, identify the leading DTx market players, and unpack the varied ways vendors reach their intended audiences. We will also assess both the opportunities and risks DTx companies and their products pose to payers, pharmaceutical companies, and medtech firms. Finally, we will forecast what we expect to see next in the DTX space and outline the barriers holding DTx firms back to help stakeholders navigate the crowding field and develop strategies to capture a piece of the DTx pie. Digital Therapeutics Companies & Startups. Here are the digital therapeutics companies and startups mentioned in this report: 23andMe, 2morrow, Inc., Advocate Health Care, Akili Interactive, Apple, Aptar Pharma, Aurora Health Care, Bayer, Better Therapeutics, Big Health, Biofourmis, Blue Shield of California, Cambia Health Solutions, Cigna, Click Therapeutics, Cognoa, CVS Caremark, DarioHealth, Dexcom, Diabeto, Eli Lilly, ExpressScripts, Glooko, Happify Health, Health2Sync, Kaia Health, Lark Health, Livongo, MedRhythms, myStrength, mySugr, Noom, Novartis, Novo Nordisk, Omada Health, Omron, One Drop, Otsuka, Pear Therapeutics, Propeller Health, Proteus Digital Health, ResMed, Retrofit, Roche, Sanofi, Teva Pharmaceutical, Teladoc, UnitedHealth Group, Vida Health, Virta Health, Voluntis, Walgreens, Walmart, and Welldoc. Here are some key takeaways from the report:  - Digital therapeutics are shaking up the healthcare value chain: The digital therapeutics market is set to triple in size over the next six years, blossoming into a $9 billion opportunity — and Business Insider Intelligence predicts consumer adoption of the digital treatments will grow more than 10-fold by 2023.  - Payers should stock portfolios with digital therapeutics to shore up on drug spending, curb their sizable share of chronic disease costs, keep patients healthy, and woo employer contracts.  - Proactive pharmaceutical firms and medical device makers can benefit from DTx's proliferation through tie-ups with vendors that give the incumbents access to piles of real-time data as well as the possibility to expand revenue opportunities through commercializing new products and programs — but sluggish drug- and device makers risk waving goodbye to consumers opting for digital solutions.  - We expect to see heightened activity in the space over the next several years, but hurdles to growth remain, including winning over doctors and consumers as well as paltry reimbursement from the Centers for Medicare and Medicaid Services.  https://www.businessinsider.com/digital-therapeutics-report